Phase 1/2 Trial of LY3884961 for Gaucher Disease Initiated by Prevail Therapeutics
Prevail Therapeutics has launched Phase 1/2 clinical trial for LY3884961 in patients with peripheral manifestations of Gaucher Disease.
Company
Pharmaceutical intelligence for Prevail Therapeutics with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.